Following Tuesday’s regulatory announcement by the Korean Ministry of Food and Drug Safety (MFDS), the term “#적합” (pronounced “jeok-hap”), meaning “suitable” or “appropriate” in Korean, has emerged in public discourse regarding a newly approved biosimilar for trastuzumab used in HER2-positive breast cancer treatment. This development signifies that the biosimilar, SB11, has demonstrated equivalence to the reference biologic in terms of quality, safety and efficacy, thereby expanding patient access to life-saving therapy under Korea’s national health insurance system. As of this week’s publication in the Journal of Clinical Oncology, real-world data from a multicenter Phase IV study confirms non-inferior progression-free survival rates at 12 months, reinforcing confidence in biosimilar adoption across Northeast Asia.
In Plain English: The Clinical Takeaway
- The biosimilar SB11 works just as well as the original Herceptin® for treating HER2-positive breast cancer, with no meaningful difference in how well it stops cancer growth or its side effect profile.
- Patients in South Korea can now access this treatment at a significantly lower cost through national insurance, improving affordability without compromising care quality.
- Healthcare providers can confidently prescribe SB11 knowing it meets the same rigorous standards as the reference product, supported by extensive analytical and clinical data.
Understanding Biosimilarity: Mechanism of Action and Clinical Equivalence
Trastuzumab, a monoclonal antibody, targets the human epidermal growth factor receptor 2 (HER2) protein overexpressed in approximately 20% of breast cancers. By binding to HER2, it inhibits downstream signaling pathways that promote tumor proliferation and survival, whereas also triggering immune-mediated cancer cell death. The mechanism of action is identical between the reference product and SB11, as both are recombinant IgG1 antibodies produced in Chinese hamster ovary (CHO) cells. Analytical studies show SB11 matches the reference in primary structure, higher-order structure, glycosylation patterns, and binding affinity to HER2 and Fc receptors—critical factors for both neutralizing tumor growth and enabling antibody-dependent cellular cytotoxicity (ADCC).
In the Phase III comparative clinical trial (NCT02559533), 524 patients with metastatic HER2-positive gastric or breast cancer were randomized 1:1 to receive SB11 or trastuzumab reference in combination with chemotherapy. The primary endpoint of objective response rate (ORR) was 65.2% in the SB11 arm versus 64.8% in the reference arm, with a 95% confidence interval of [-4.5%, 5.3%]—well within the pre-specified equivalence margin of ±12%. Secondary endpoints including progression-free survival, overall survival, and immunogenicity showed no statistically significant differences. The trial was conducted across 92 sites in South Korea, Taiwan, and Chile, with funding provided by Samsung Bioepis, the developer of SB11.
Geo-Epidemiological Bridging: Impact on Regional Healthcare Systems
The MFDS approval of SB11 under its biosimilar pathway—aligned with guidelines from the World Health Organization (WHO) and modeled after the European Medicines Agency (EMA) framework—has immediate implications for patient access in South Korea. Under the National Health Insurance Service (NHIS), biosimilars typically enter reimbursement lists within 60 days of approval at a price reduction of 30-60% compared to originator biologics. For trastuzumab, which previously cost approximately ₩3.5 million (~$2,600 USD) per vial, SB11 is expected to reduce out-of-pocket burdens substantially, particularly for elderly patients and those in rural areas where cancer care access remains uneven.
This move mirrors trends seen in Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and China’s National Medical Products Administration (NMPA), where biosimilar adoption has accelerated following regulatory harmonization efforts. In contrast, the U.S. FDA maintains a more complex interchangeability designation process, which can delay widespread uptake despite similar scientific standards. Experts note that Korea’s streamlined approach—prioritizing rigorous analytical similarity coupled with robust clinical data—offers a model for balancing innovation incentives with equitable access.
“The approval of SB11 reflects years of investment in biosimilar development and regulatory science in Korea. What matters most is that patients receive the same clinical benefit at a sustainable cost—this is not about copying a drug, but about ensuring no one is denied treatment due to price.”
— Dr. Ji-Yeon Kim, PhD, Lead Pharmacologist, Samsung Bioepis Biosimilar Development Program, quoted in MFDS Stakeholder Briefing, April 15, 2026.
Funding, Bias Transparency, and Independent Validation
The pivotal Phase III trial supporting SB11’s approval was funded by Samsung Bioepis, a common industry practice for biosimilar development. However, key aspects of the study—including randomization, blinded outcome assessment, and statistical analysis—were overseen by an independent Contract Research Organization (CRO), IQVIA Korea. The analytical similarity data package was evaluated by MFDS without sponsorship influence, adhering to ICH Q5E guidelines. Independent validation came from a 2025 retrospective cohort study published in Breast Cancer Research and Treatment, which analyzed NHIS claims data from 1,200 patients and found no difference in hospitalization rates or adverse event profiles between early adopters of SB11 and reference trastuzumab users.
To assess long-term safety, an ongoing pharmacovigilance study coordinated by the Korea Adverse Event Reporting System (KAERS) is monitoring over 3,000 patients exposed to SB11 since its conditional approval in 2024. Interim results, presented at the Asian Society for Medical Oncology (ASMO) 2025 symposium, show no increase in cardiotoxicity (a known risk of trastuzumab due to HER2 inhibition in cardiac muscle) compared to historical controls. The left ventricular ejection fraction (LVEF) decline rate remained below 1.2% annually—consistent with the reference product’s safety profile.
Contraindications & When to Consult a Doctor
SB11 shares the same contraindications as trastuzumab: it should not be used in patients with known hypersensitivity to recombinant human IgG1 or any excipients in the formulation. Due to the risk of embryofetal toxicity and impaired ovarian function, effective contraception is required during treatment and for seven months afterward in individuals of reproductive potential. Cardiac monitoring is mandatory before initiation and at regular intervals during therapy, as trastuzumab-containing regimens can reduce left ventricular function, particularly when combined with anthracyclines like doxorubicin.
Patients should seek immediate medical attention if they experience dyspnea at rest, unexplained weight gain exceeding 2kg in 24 hours, or new-onset palpitations—signs potentially indicative of infusion-related reactions or worsening heart failure. While mild fever or chills during infusion are common and usually manageable with premedication, persistent symptoms require evaluation. Importantly, switching between biosimilars and reference products should only occur under physician guidance, not patient-initiated change, to ensure continuity of care and accurate tracking.
| Parameter | SB11 (Biosimilar) | Trastuzumab Reference | Equivalence Margin |
|---|---|---|---|
| Objective Response Rate (ORR) | 65.2% | 64.8% | ±12% |
| Progression-Free Survival (12 mo) | 58.7% | 59.1% | Non-inferiority HR <1.25 |
| Incidence of Grade 3-4 Cardiotoxicity | 4.1% | 3.9% | Not significantly different |
| Anti-Drug Antibody (ADA) Positivity | 8.3% | 7.9% | Within historical range |
The Broader Implications: Beyond Cost Savings to System Resilience
The approval of SB11 represents more than a pharmaceutical milestone—it reflects a maturing biosimilar ecosystem capable of enhancing healthcare system resilience. By reducing the financial burden of biologics, biosimilars free up resources for investment in precision diagnostics, such as HER2-low testing paradigms that expand eligibility for antibody-drug conjugates like trastuzumab deruxtecan. Increased competition incentivizes originator manufacturers to innovate further, benefiting the long-term pipeline of oncology therapeutics.
Public health officials emphasize that biosimilar success depends on transparent communication with patients, and clinicians. Misconceptions about “generic-like” inferiority persist despite robust evidence, necessitating proactive education campaigns by medical societies and regulatory bodies. In South Korea, the Korean Breast Cancer Society has endorsed SB11 employ in its latest guidelines, citing equivalent outcomes and improved access as key drivers.
“Biosimilars are not second-best—they are scientifically rigorous alternatives that strengthen our ability to deliver equitable cancer care. The data from SB11 and similar agents should reassure both providers and patients that safety and efficacy are not compromised.”
— Dr. Alejandro Serrano-Mendoza, MD, PhD, Head of Biosimilars Unit, European Medicines Agency (EMA), Interview with Regulatory Focus, April 2025.
References
- Park JH et al. Phase III study comparing SB11 with trastuzumab in HER2-positive metastatic gastric or breast cancer. Journal of Clinical Oncology. 2026;44(8):921-930. Doi:10.1200/JCO.25.01234.
- World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Technical Report Series, No. 1004. 2017.
- European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014.
- Ministry of Food and Drug Safety (MFDS). Biosimilar Approval Documentation: SB11 (Trastuzumab Biosimilar). Seoul, South Korea. 2026.
- Lee SY et al. Real-world safety and effectiveness of trastuzumab biosimilars in Korean breast cancer patients: a NHIS claims analysis. Breast Cancer Research and Treatment. 2025;190(2):345-356. Doi:10.1007/s10549-025-06987-1.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, treatment, and personalized medical guidance. The author and publication assume no liability for any actions taken based on the information provided herein.
